Amplifon SpAAMFPF 78 EV-to-EBIT is 24.34 as of Jul. 09, 2026, which is 16% below its 10-year median of 28.92. GuruFocus rates AMFPF with a GF Score™ of 78/100 and a GF Value™ of $28.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 93 Medical Distribution companies, Amplifon SpA ranks worse than 86.02% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amplifon SpA's Enterprise Value for the quarter that ended in Mar. 2026 was $3,929 Mil.
Amplifon SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $197 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplifon SpA EV-to-EBIT Related Terms
Amplifon SpA EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Amplifon SpA's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Amplifon SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplifon SpA EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amplifon SpA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amplifon SpA's EV-to-EBIT falls into.
Amplifon SpA's current Enterprise Value is $4,805 Mil.
Amplifon SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $197 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplifon SpA (AMFPF) has a EV-to-EBIT of 24.34 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amplifon SpA and its competitors. This is 16% below median its historical median of 28.92. Over the past decade, Amplifon SpA's EV-to-EBIT has ranged from 16.95 to 67.26. According to the industry distribution chart, Amplifon SpA ranks #80 out of 93 companies in the Medical Distribution industry, placing it in the top 86%.
Is Amplifon SpA's EV-to-EBIT too high?
Amplifon SpA's current EV-to-EBIT of 24.34 is 16% below median its 10-year median of 28.92. Over the past 10 years, this metric has ranged from a low of 16.95 to a high of 67.26. The Medical Distribution industry median EV-to-EBIT is 11.98. Amplifon SpA's value of 24.34 is 103.2% above this industry median. Based on the distribution chart, Amplifon SpA ranks #80 out of 93 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Amplifon SpA has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Amplifon SpA's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Amplifon SpA ranks #80 out of 93 companies for EV-to-EBIT. This places Amplifon SpA in the lower half of its industry. The industry median EV-to-EBIT is 11.98. Amplifon SpA's value of 24.34 is 103.2% above this benchmark. Historically, Amplifon SpA's own EV-to-EBIT has ranged from 16.95 to 67.26 over the past decade. While the company's 10-year median is 28.92 vs. the industry median of 11.98, Amplifon SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.98, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplifon SpA's current EV-to-EBIT of 24.34 is 103.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amplifon SpA and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplifon SpA's current EV-to-EBIT is 24.34, which is 16% below median its own 10-year median of 28.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplifon SpA stock overvalued right now?
Based on GuruFocus' analysis, Amplifon SpA (AMFPF) is currently considered Possible Value Trap. The stock's GF Value™ is $28.60, compared to a current price of $11.21 — trading 60.8% below its estimated fair value. The current EV-to-EBIT is 24.34, which is 16% below median its 10-year median of 28.92 and 103.2% above the Medical Distribution industry median of 11.98. Amplifon SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Amplifon SpA (AMFPF), the current EV-to-EBIT is 24.34 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amplifon SpA (AMFPF) Overvalued in 2026?
Based on GuruFocus' analysis, Amplifon SpA stock appears to be undervalued.
The current stock price of $11.21 is trading 60.8% below its estimated GF Value™ of $28.60.
GuruFocus considers Amplifon SpA to be Possible Value Trap.
Key valuation signals for AMFPF:
EV-to-EBIT: 24.34 (16% below median its 10-year median of 28.92)
GF Value™: $28.60 vs. price of $11.21 (60.8% below fair value)
Industry Position: 103.2% above the Medical Distribution median (#80 of 93)
No single metric tells the full story. See the AMFPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amplifon SpA provides customizable hearing solutions and services through a distribution network of network affiliates, corporate shops, franchises, and shop-in-shops. The company operates in three segments based on geography: the Americas; Europe, the Middle East, and Africa; and Asia-Pacific. It generates the majority of its revenue in the EMEA region. It operates under a variety of brands in these regions, including Amplifon, Beter Horen, Maxtone, and Miracle-Ear.
78GF Score
Get the complete analysis for AMFPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMFPF has been successfully added to your 
